Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis. - Conaghan, Philip; Cohen, Stanley; Burmester, Gerd; Mysler, Eduardo; Nash, Peter; Tanaka, Yoshiya; Rigby, William; Patel, Jayeshkumar; Shaw, Tim; Betts, Keith A.; Patel, Pankaj; Liu, Jianzhong; et al. (Rheumatology & Therapy, 2022)